Overview
Biopharmaceutical company's 2025 revenue grew 19.8% yr/yr, beating analyst expectations
Company's Q4 revenue rose 7.6% yr/yr, driven by FIRDAPSE and AGAMREE growth
Company announced $200 mln share repurchase program
Outlook
Full year 2026 revenues expected between $615 mln and $645 mln
FIRDAPSE 2026 revenue forecast between $435 mln and $450 mln
AGAMREE 2026 revenue forecast between $140 mln and $150 mln
Result Drivers
FIRDAPSE GROWTH - FIRDAPSE revenue increased 18.3% in Q4 2025, driven by expanded use in treating LEMS
AGAMREE UPTAKE - AGAMREE revenue grew 67.5% in Q4 2025, reflecting strong market adoption
Company press release: ID:nGNX60V34y
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
$589 mln
$578.41 mln (7 Analysts)
FY Net Income
$214.3 mln
FY Operating Income
$257.8 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Catalyst Pharmaceuticals Inc is $34.00, about 40.6% above its February 24 closing price of $24.19
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
